Abstract

BackgroundHepatocarcinogenesis is reportedly correlated with abnormal m6A modifications; however, it is unknown whether m6A RNA methylation regulators facilitate the occurrence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Thus, we constructed an m6A-related model that may enhance HBV-related HCC prognosis.MethodsGene signatures of HNRNPA2B1 and RBM15 were generated by univariate and Lasso Cox regression analyses using the gene set and clinical information from The Cancer Genome Atlas (TCGA) database. High-risk and low-risk groups were confirmed based on the gene signature model. Furthermore, we validated the predictive roles of the two genes for overall survival (OS) in the GSE14520 dataset. The relative expression of 22 paired mRNAs was measured using quantitative real-time polymerase chain reaction (qRT-PCR) analysis to determine whether the two genes had a predictive role in our Guilin cohort.ResultsThe differences in OS between the high-risk and low-risk groups were statistically significant in the TCGA (p = 0.003) and GSE14520 (p = 0.045) datasets, but not in the Guilin cohort, owing to differences in clinical information among the three cohorts (mainly the TNM stage and survival state). Stratified analysis of TNM stages showed that the two-gene signature acted as a prognostic indicator of HBV-related HCC patients in the early TNM stage; both TCGA and GSE14520 cohorts showed statistical significance. Moreover, multivariate Cox regression analysis indicated that the two-gene signature was an independent factor for predicting prognosis (HR = 1.087, 95% CI: 1.007–1.172). Correlation analysis between the gene signature and clinical features revealed that the risk stratification was significantly correlated with grade and survival state. Finally, Gene Set Enrichment Analysis (GSEA) revealed that the KEGG pathways associated with the cell cycle, DNA replication, the spliceosome, repair, and metabolism-related processes were all significantly enriched in the high-risk group. Among the enriched genes, the expression levels of the replication protein RPA1 and the pre-mRNA splicing factor SF3B1 were significantly upregulated in the high-risk group. These results might help in elucidating the underlying molecular mechanisms of HBV-related HCC.ConclusionsOur data may provide new predictive signatures and potential therapeutic targets to identify and treat HBV-related HCC patients in the early disease stage.

Highlights

  • Hepatocarcinogenesis is reportedly correlated with abnormal m6A modifications; it is unknown whether m6A RNA methylation regulators facilitate the occurrence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC)

  • Chen et al found that high METTL3 expression in human HCC leads to high m6A levels in SOCS2 messenger RNAs (mRNAs), which causes the rapid degradation of SOCS2 and eventually leads to HCC occurrence (Chen et al 2018)

  • Identification of the differentially expressed m6A regulators Out of the 21 m6A regulatory genes, 18 differentially expressed genes were identified in the tumor tissues (n = 93) and healthy tissues (n = 50) in the The Cancer Genome Atlas (TCGA) dataset

Read more

Summary

Introduction

Hepatocarcinogenesis is reportedly correlated with abnormal m6A modifications; it is unknown whether m6A RNA methylation regulators facilitate the occurrence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). N6-methyladenosine (m6A), which occurs in the messenger RNAs (mRNAs) of most eukaryotes, is the most prevalent modification of mammalian RNA (Desrosiers et al 1974) This modification is mediated by a series of protein factors, including the writer complex subunits (METTL3, METTL14, WTAP, RBM15, KIAA1429, and ZC3H13), erasers (FTO and ALKBH5), and readers (YTHDF1/2/3, YTHDC1/2, eIF3, IGF2BP1/2/3, HNRNPA2B1, FMR1, and LRPPRC) (Wang et al 2018a). These m6A regulators exert enormous influence on cancer development processes such as proliferation, migration, and invasion (Liu et al 2018). Ma et al found that METTL14 had no remarkable effect on HCC; METTL14 downregulation was correlated with poor prognosis in HCC patients without recurrence (Ma et al 2017)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call